{"id":"apatinib-mesylate-gefitinib","safety":{"commonSideEffects":[{"rate":"34%","effect":"Diarrhea"},{"rate":"24%","effect":"Fatigue"},{"rate":"21%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Apatinib mesylate is a potent inhibitor of VEGFR-2 and c-KIT tyrosine kinases, which are involved in tumor angiogenesis and cell proliferation.","oneSentence":"Tyrosine kinase inhibitor of VEGFR-2 and c-KIT","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:53:39.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04390984","phase":"PHASE1","title":"Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-05-26","conditions":"NSCLC","enrollment":22},{"nctId":"NCT03267654","phase":"PHASE2","title":"Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2017-10-12","conditions":"Non-small-cell Lung Cancer","enrollment":100},{"nctId":"NCT03461185","phase":"PHASE2","title":"Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2018-05-01","conditions":"Non Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT03389256","phase":"PHASE2","title":"Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2018-12-30","conditions":"Lung Diseases, Neoplasms, Respiratory Tract Diseases","enrollment":144},{"nctId":"NCT03050411","phase":"PHASE1","title":"Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2016-05","conditions":"Nonsmall Cell Lung Cancer","enrollment":30},{"nctId":"NCT02824458","phase":"PHASE3","title":"A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-06","conditions":"EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors","enrollment":246}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Apatinib Mesylate, Gefitinib","genericName":"Apatinib Mesylate, Gefitinib","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tyrosine kinase inhibitor of VEGFR-2 and c-KIT Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}